Literature DB >> 3578334

Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses.

T Bergan, S B Thorsteinsson, R Solberg, L Bjornskau, I M Kolstad, S Johnsen.   

Abstract

The pharmacokinetics of ciprofloxacin, after administration of single oral doses of 100, 250, 500, and 1,000 mg, and an intravenous dose of 100 mg, were determined in 12 healthy volunteers (six women and six men). Serum concentrations were determined by high-pressure liquid chromatography, and urine samples were assayed microbiologically. The peak serum concentrations and the total areas under the serum concentration curves increased in proportion to the size of the oral dose. The pharmacokinetics of ciprofloxacin were described by a dose-independent linear relationship. The apparent oral bioavailability was 85 percent, based on comparison of the total areas under the serum concentration curves of the 100-mg dose. The serum concentrations during steady state were not significantly higher than after the first dose. The serum half-life ranged from 3.0 to 3.4 hours after the oral doses, and was 2.9 hours after the intravenous dose. The elimination-phase apparent distribution volume coefficient, delta d,area, was 2.76 liters/kg, and the total body clearance was 42.0 liters/hour. The 24-hour urinary excretion was 42.2 +/- 15.6 percent after the 100-mg intravenous dose and 42.5 +/- 17.6 percent after the 500-mg twice-daily oral dose during steady state.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3578334

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  19 in total

1.  Investigation of potential interaction of ciprofloxacin with cyclosporine in bone marrow transplant recipients.

Authors:  H U Krüger; U Schuler; B Proksch; M Göbel; G Ehninger
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding.

Authors:  J H Yuk; C H Nightingale; K R Sweeney; R Quintiliani; J T Lettieri; R W Frost
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

3.  Use of ciprofloxacin in biliary sepsis.

Authors:  C J Chrysanthopoulos; A T Skoutelis; J C Starakis; A Arvaniti; H P Bassaris
Journal:  Infection       Date:  1988 Jul-Aug       Impact factor: 3.553

4.  Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule.

Authors:  S Harder; U Fuhr; D Beermann; A H Staib
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

5.  Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics.

Authors:  H Stuht; H Lode; P Koeppe; K L Rost; T Schaberg
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

Review 6.  Pharmacokinetics of the newer fluoroquinolones.

Authors:  J R Brouwers
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

7.  Ciprofloxacin concentrations and impact of the colon microflora in patients undergoing colorectal surgery.

Authors:  B Brismar; C Edlund; A S Malmborg; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

8.  Biliary tract infections treated with ciprofloxacin.

Authors:  G N Karachalios; G Zografos; V Patrikakos; D Nassopoulou; K Kehagioglou
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

9.  Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society.

Authors:  T J Louie
Journal:  CMAJ       Date:  1994-03-01       Impact factor: 8.262

Review 10.  Quinolones in the elderly.

Authors:  T Bergan
Journal:  Drugs       Date:  1995       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.